Top

Published in:

01-06-2019 | Melanoma | Review Article

N-Glycosylation in progression of skin cancer

Authors: Ling Tang, Xiaoping Chen, Xu Zhang, Yeye Guo, Juan Su, Jianglin Zhang, Cong Peng, Xiang Chen

Published in: Medical Oncology | Issue 6/2019

Abstract

Skin cancer can be classified as cutaneous malignant melanoma, basal cell carcinoma, and squamous cell carcinoma. Due to the high level of morbidity and mortality, skin cancer has become a global public health issue worldwide while the pathogenesis of skin cancer is still unclear. It is necessary to further identify the pathogenesis of skin cancer and find candidate targets to diagnose and treat skin cancer. A variety of factors are known to be associated with skin cancer including N-glycosylation, which partly explained the malignant behaviors of skin cancer. In this review, we retrieved databases such as PubMed and Web of Science to elucidate its relationship between glycosylation and skin cancer. We summarized some key glycosyltransferases and proteins during the process of N-glycosylation related to skin cancer, which was helpful to unmask the additional mechanism of skin cancer and find some novel targets of skin cancer.

Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol. 2014;810:120–40.PubMed

Tracey EH, Vij A. Updates in melanoma. Dermatol Clin. 2019;37(1):73–82. https://doi.org/10.1016/j.det.2018.08.003.CrossRefPubMed

Fahradyan A, Howell AC, Wolfswinkel EM, Tsuha M, Sheth P, Wong AK. Updates on the management of non-melanoma skin cancer (NMSC). Healthcare. 2017. https://doi.org/10.3390/healthcare5040082.CrossRefPubMedPubMedCentral

Geller AC, Colditz G, Oliveria S, Emmons K, Jorgensen C, Aweh GN, et al. Use of sunscreen, sunburning rates, and tanning bed use among more than 10 000 US children and adolescents. Pediatrics. 2002;109(6):1009–14.CrossRefPubMed

Chahal HS, Lin Y, Ransohoff KJ, Hinds DA, Wu W, Dai HJ, et al. Genome-wide association study identifies novel susceptibility loci for cutaneous squamous cell carcinoma. Nat Commun. 2016;7:12048. https://doi.org/10.1038/ncomms12048.CrossRefPubMedPubMedCentral

Buster KJ, You Z, Fouad M, Elmets C. Skin cancer risk perceptions: a comparison across ethnicity, age, education, gender, and income. J Am Acad Dermatol. 2012;66(5):771–9. https://doi.org/10.1016/j.jaad.2011.05.021.CrossRefPubMed

Kinslechner K, Schorghofer D, Schutz B, Vallianou M, Wingelhofer B, Mikulits W, et al. Malignant phenotypes in metastatic melanoma are governed by SR-BI and its association with glycosylation and STAT5 activation. Mol Cancer Res. 2018;16(1):135–46. https://doi.org/10.1158/1541-7786.mcr-17-0292.CrossRefPubMed

Bond MR, Hanover JA. A little sugar goes a long way: the cell biology of O-GlcNAc. J Cell Biol. 2015;208(7):869–80. https://doi.org/10.1083/jcb.201501101.CrossRefPubMedPubMedCentral

Khoury GA, Baliban RC, Floudas CA. Proteome-wide post-translational modification statistics: frequency analysis and curation of the swiss-prot database. Sci Rep. 2011. https://doi.org/10.1038/srep00090.CrossRefPubMedPubMedCentral

10.

Achalli S, Madi M, Babu SG, Shetty SR, Kumari S, Bhat S. Sialic acid as a biomarker of oral potentially malignant disorders and oral cancer. Indian J Dent Res. 2017;28(4):395–9. https://doi.org/10.4103/ijdr.IJDR_632_16.CrossRefPubMed

11.

Helenius A, Aebi M. Intracellular functions of N-linked glycans. Science. 2001;291(5512):2364–9.CrossRefPubMed

12.

Banerjee DK. N-glycans in cell survival and death: cross-talk between glycosyltransferases. Biochem Biophys Acta. 2012;1820(9):1338–46. https://doi.org/10.1016/j.bbagen.2012.01.013.CrossRefPubMed

13.

Konopka JB. N-acetylglucosamine (GlcNAc) functions in cell signaling. Scientifica. 2012. https://doi.org/10.6064/2012/489208.CrossRefPubMedPubMedCentral

14.

Wang X, He H, Zhang H, Chen W, Ji Y, Tang Z, et al. Clinical and prognostic implications of beta1, 6-N-acetylglucosaminyltransferase V in patients with gastric cancer. Cancer Sci. 2013;104(2):185–93. https://doi.org/10.1111/cas.12049.CrossRefPubMed

15.

Huang C, Huang M, Chen W, Zhu W, Meng H, Guo L, et al. N-acetylglucosaminyltransferase V modulates radiosensitivity and migration of small cell lung cancer through epithelial–mesenchymal transition. FEBS J. 2015;282(22):4295–306. https://doi.org/10.1111/febs.13419.CrossRefPubMed

16.

Liu Y, Liu H, Liu W, Zhang W, An H, Xu J. Beta1,6-N-acetylglucosaminyltransferase V predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection. World J Urol. 2015;33(11):1791–9. https://doi.org/10.1007/s00345-014-1451-x.CrossRefPubMed

17.

Pochec E, Rydlewska M, Przybylo M, Litynska A. Diverse expression of N-acetylglucosaminyltransferase V and complex-type beta1,6-branched N-glycans in uveal and cutaneous melanoma cells. Acta Biochim Pol. 2015;62(2):323–8. https://doi.org/10.18388/abp.2015_1050.CrossRefPubMed

18.

Narasimhan S. Control of glycoprotein synthesis. UDP-GlcNAc:glycopeptide beta 4-N-acetylglucosaminyltransferase III, an enzyme in hen oviduct which adds GlcNAc in beta 1-4 linkage to the beta-linked mannose of the trimannosyl core of N-glycosyl oligosaccharides. J Biol Chem. 1982;257(17):10235–42.PubMed

19.

Allam H, Johnson BP, Zhang M, Lu Z, Cannon MJ, Abbott KL. The glycosyltransferase GnT-III activates Notch signaling and drives stem cell expansion to promote the growth and invasion of ovarian cancer. J Biol Chem. 2017;292(39):16351–9. https://doi.org/10.1074/jbc.M117.783936.CrossRefPubMedPubMedCentral

20.

Yoshimura M, Ihara Y, Taniguchi N. Changes of beta-1,4-N-acetylglucosaminyltransferase III (GnT-III) in patients with leukaemia. Glycoconj J. 1995;12(3):234–40.CrossRefPubMed

21.

Yoshimura M, Nishikawa A, Ihara Y, Taniguchi S, Taniguchi N. Suppression of lung metastasis of B16 mouse melanoma by N-acetylglucosaminyltransferase III gene transfection. Proc Natl Acad Sci USA. 1995;92(19):8754–8.CrossRefPubMedPubMedCentral

22.

Li W, Takahashi M, Shibukawa Y, Yokoe S, Gu J, Miyoshi E, et al. Introduction of bisecting GlcNAc in N-glycans of adenylyl cyclase III enhances its activity. Glycobiology. 2007;17(6):655–62. https://doi.org/10.1093/glycob/cwm022.CrossRefPubMed

23.

Kariya Y, Kato R, Itoh S, Fukuda T, Shibukawa Y, Sanzen N, et al. N-glycosylation of laminin-332 regulates its biological functions. A novel function of the bisecting GlcNAc. J Biol Chem. 2008;283(48):33036–45. https://doi.org/10.1074/jbc.m804526200.CrossRefPubMedPubMedCentral

24.

Kariya Y, Kawamura C, Tabei T, Gu J. Bisecting GlcNAc residues on laminin-332 down-regulate galectin-3-dependent keratinocyte motility. J Biol Chem. 2010;285(5):3330–40. https://doi.org/10.1074/jbc.M109.038836.CrossRefPubMed

25.

Lu J, Isaji T, Im S, Fukuda T, Kameyama A, Gu J. Expression of N-acetylglucosaminyltransferase III suppresses alpha2,3-sialylation, and its distinctive functions in cell migration are attributed to alpha2,6-sialylation levels. J Biol Chem. 2016;291(11):5708–20. https://doi.org/10.1074/jbc.M115.712836.CrossRefPubMedPubMedCentral

26.

Dennis JW, Granovsky M, Warren CE. Glycoprotein glycosylation and cancer progression. Biochem Biophys Acta. 1999;1473(1):21–34.CrossRefPubMed

27.

Przybylo M, Martuszewska D, Pochec E, Hoja-Lukowicz D, Litynska A. Identification of proteins bearing beta1-6 branched N-glycans in human melanoma cell lines from different progression stages by tandem mass spectrometry analysis. Biochem Biophys Acta. 2007;1770(9):1427–35. https://doi.org/10.1016/j.bbagen.2007.05.006.CrossRefPubMed

28.

Przybylo M, Pochec E, Link-Lenczowski P, Litynska A. Beta1-6 branching of cell surface glycoproteins may contribute to uveal melanoma progression by up-regulating cell motility. Mol Vis. 2008;14:625–36.PubMedPubMedCentral

29.

Pochec E, Zabczynska M, Bubka M, Homa J, Litynska A. Beta1,6-branched complex-type N-glycans affect FAK signaling in metastatic melanoma cells. Cancer Invest. 2016;34(1):45–56. https://doi.org/10.3109/07357907.2015.1102928.CrossRefPubMed

30.

Taniguchi N, Miyoshi E, Ko JH, Ikeda Y, Ihara Y. Implication of N-acetylglucosaminyltransferases III and V in cancer: gene regulation and signaling mechanism. Biochem Biophys Acta. 1999;1455(2–3):287–300.PubMed

31.

Tedaldi LM, Pierce M, Wagner GK. Optimised chemical synthesis of 5-substituted UDP-sugars and their evaluation as glycosyltransferase inhibitors. Carbohydr Res. 2012;364:22–7. https://doi.org/10.1016/j.carres.2012.10.009.CrossRefPubMed

32.

Hanashima S, Inamori K, Manabe S, Taniguchi N, Ito Y. Systematic synthesis of bisubstrate-type inhibitors of N-acetylglucosaminyltransferases. Chemistry. 2006;12(13):3449–62. https://doi.org/10.1002/chem.200501348.CrossRefPubMed

33.

Hassani Z, Saleh A, Turpault S, Khiati S, Morelle W, Vignon J, et al. Phostine PST3.1a targets MGAT5 and inhibits glioblastoma-initiating cell invasiveness and proliferation. Mol Cancer Res. 2017;15(10):1376–87. https://doi.org/10.1158/1541-7786.mcr-17-0120.CrossRefPubMed

34.

Zhang J, Liu Y, Deng X, Chen L, Yang X, Yu C. ST6GAL1 negatively regulates monocyte transendothelial migration and atherosclerosis development. Biochem Biophys Res Commun. 2018;500(2):249–55. https://doi.org/10.1016/j.bbrc.2018.04.053.CrossRefPubMed

35.

Chakraborty A, Dorsett KA, Trummell HQ, Yang ES, Oliver PG, Bonner JA, et al. ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage. J Biol Chem. 2018;293(3):984–94. https://doi.org/10.1074/jbc.M117.808584.CrossRefPubMed

36.

Kolasinska E, Przybylo M, Janik M, Litynska A. Towards understanding the role of sialylation in melanoma progression. Acta Biochim Pol. 2016;63(3):533–41. https://doi.org/10.18388/abp.2015_1221.CrossRefPubMed

37.

Laidler P, Litynska A, Hoja-Lukowicz D, Labedz M, Przybylo M, Ciolczyk-Wierzbicka D, et al. Characterization of glycosylation and adherent properties of melanoma cell lines. Cancer Immunol Immunother. 2006;55(1):112–8. https://doi.org/10.1007/s00262-005-0019-4.CrossRefPubMed

38.

Ferreira SA, Vasconcelos JL, Silva RC, Cavalcanti CL, Bezerra CL, Rego MJ, et al. Expression patterns of alpha2,3-sialyltransferase I and alpha2,6-sialyltransferase I in human cutaneous epithelial lesions. Eur J Histochem. 2013;57(1):e7. https://doi.org/10.4081/ejh.2013.e7.CrossRefPubMed

39.

Ranjan A, Kalraiya RD. α2,6 Sialylation associated with increased β1,6-branched N-oligosaccharides influences cellular adhesion and invasion. J Biosci. 2013;38(5):867–76. https://doi.org/10.1007/s12038-013-9382-z.CrossRefPubMed

40.

Tu CF, Wu MY, Lin YC, Kannagi R, Yang RB. FUT8 promotes breast cancer cell invasiveness by remodeling TGF-beta receptor core fucosylation. Breast Cancer Res. 2017;19(1):111. https://doi.org/10.1186/s13058-017-0904-8.CrossRefPubMedPubMedCentral

41.

Wang Y, Fukuda T, Isaji T, Lu J, Im S, Hang Q, et al. Loss of alpha1,6-fucosyltransferase inhibits chemical-induced hepatocellular carcinoma and tumorigenesis by down-regulating several cell signaling pathways. FASEB J. 2015;29(8):3217–27. https://doi.org/10.1096/fj.15-270710.CrossRefPubMed

42.

Ciolczyk-Wierzbicka D, Bodzioch M, Gil D, Zmudzinska D, Dembinska-Kiec A, Laidler P. Expression of fucosyltransferases contributes to melanoma invasive phenotype. Med Chem. 2007;3(5):418–24.CrossRefPubMed

43.

Lau E, Feng Y, Claps G, Fukuda MN, Perlina A, Donn D, et al. The transcription factor ATF2 promotes melanoma metastasis by suppressing protein fucosylation. Sci Signal. 2015;8(406):ra124. https://doi.org/10.1126/scisignal.aac6479.CrossRefPubMedPubMedCentral

44.

Agrawal P, Fontanals-Cirera B, Sokolova E, Jacob S, Vaiana CA, Argibay D, et al. A systems biology approach identifies FUT8 as a driver of melanoma metastasis. Cancer Cell. 2017;31(6):804–819.e7. https://doi.org/10.1016/j.ccell.2017.05.007.CrossRefPubMedPubMedCentral

45.

Manabe Y, Kasahara S, Takakura Y, Yang X, Takamatsu S, Kamada Y, et al. Development of alpha1,6-fucosyltransferase inhibitors through the diversity-oriented syntheses of GDP-fucose mimics using the coupling between alkyne and sulfonyl azide. Bioorg Med Chem. 2017;25(11):2844–50. https://doi.org/10.1016/j.bmc.2017.02.036.CrossRefPubMed

46.

Moremen KW, Tiemeyer M, Nairn AV. Vertebrate protein glycosylation: diversity, synthesis and function. Nat Rev Mol Cell Biol. 2012;13(7):448–62. https://doi.org/10.1038/nrm3383.CrossRefPubMedPubMedCentral

47.

Apweiler R, Hermjakob H, Sharon N. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochem Biophys Acta. 1999;1473(1):4–8.CrossRefPubMed

48.

Kirwan A, Utratna M, O’Dwyer ME, Joshi L, Kilcoyne M. Glycosylation-based serum biomarkers for cancer diagnostics and prognostics. Biomed Res Int. 2015;2015:490531. https://doi.org/10.1155/2015/490531.CrossRefPubMedPubMedCentral

49.

Pandolfi F, Franza L, Altamura S, Mandolini C, Cianci R, Ansari A, et al. Integrins: integrating the biology and therapy of cell–cell interactions. Clin Ther. 2017;39(12):2420–36. https://doi.org/10.1016/j.clinthera.2017.11.002.CrossRefPubMed

50.

Oz OK, Campbell A, Tao TW. Reduced cell adhesion to fibronectin and laminin is associated with altered glycosylation of beta 1 integrins in a weakly metastatic glycosylation mutant. Int J Cancer. 1989;44(2):343–7.CrossRefPubMed

51.

Kawano T, Takasaki S, Tao TW, Kobata A. Altered glycosylation of beta 1 integrins associated with reduced adhesiveness to fibronectin and laminin. Int J Cancer. 1993;53(1):91–6.CrossRefPubMed

52.

Pochec E, Litynska A, Amoresano A, Casbarra A. Glycosylation profile of integrin alpha 3 beta 1 changes with melanoma progression. Biochem Biophys Acta. 2003;1643(1–3):113–23.CrossRefPubMed

53.

Isaji T, Gu J, Nishiuchi R, Zhao Y, Takahashi M, Miyoshi E, et al. Introduction of bisecting GlcNAc into integrin alpha5beta1 reduces ligand binding and down-regulates cell adhesion and cell migration. J Biol Chem. 2004;279(19):19747–54. https://doi.org/10.1074/jbc.M311627200.CrossRefPubMed

54.

Johnson JP. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev. 1999;18(3):345–57.CrossRefPubMed

55.

Litynska A, Przybylo M, Pochec E, Kremser E, Hoja-Lukowicz D, Sulowska U. Does glycosylation of melanoma cells influence their interactions with fibronectin? Biochimie. 2006;88(5):527–34. https://doi.org/10.1016/j.biochi.2005.10.012.CrossRefPubMed

56.

Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G, et al. High incidence of EMMPRIN expression in human tumors. Int J Cancer. 2006;119(8):1800–10. https://doi.org/10.1002/ijc.22062.CrossRefPubMed

57.

Kanekura T, Chen X. CD147/basigin promotes progression of malignant melanoma and other cancers. J Dermatol Sci. 2010;57(3):149–54. https://doi.org/10.1016/j.jdermsci.2009.12.008.CrossRefPubMed

58.

Nishibaba R, Higashi Y, Su J, Furukawa T, Kawai K, Kanekura T. CD147-targeting siRNA inhibits cell–matrix adhesion of human malignant melanoma cells by phosphorylating focal adhesion kinase. J Dermatol. 2012;39(1):63–7. https://doi.org/10.1111/j.1346-8138.2011.01304.x.CrossRefPubMed

59.

Li J, Peng L, Wu L, Kuang Y, Su J, Yi M, et al. Depletion of CD147 sensitizes human malignant melanoma cells to hydrogen peroxide-induced oxidative stress. J Dermatol Sci. 2010;58(3):204–10. https://doi.org/10.1016/j.jdermsci.2010.03.022.CrossRefPubMed

60.

Zeng W, Su J, Wu L, Yang D, Long T, Li D, et al. CD147 promotes melanoma progression through hypoxia-induced MMP2 activation. Curr Mol Med. 2014;14(1):163–73.CrossRefPubMed

61.

Hatanaka M, Higashi Y, Fukushige T, Baba N, Kawai K, Hashiguchi T, et al. Cleaved CD147 shed from the surface of malignant melanoma cells activates MMP2 produced by fibroblasts. Anticancer Res. 2014;34(12):7091–6.PubMed

62.

Luo Z, Zeng W, Tang W, Long T, Zhang J, Xie X, et al. CD147 interacts with NDUFS6 in regulating mitochondrial complex I activity and the mitochondrial apoptotic pathway in human malignant melanoma cells. Curr Mol Med. 2014;14(10):1252–64.CrossRefPubMed

63.

Bai Y, Huang W, Ma LT, Jiang JL, Chen ZN. Importance of N-glycosylation on CD147 for its biological functions. Int J Mol Sci. 2014;15(4):6356–77. https://doi.org/10.3390/ijms15046356.CrossRefPubMedPubMedCentral

64.

Huang W, Luo WJ, Zhu P, Tang J, Yu XL, Cui HY, et al. Modulation of CD147-induced matrix metalloproteinase activity: role of CD147 N-glycosylation. Biochem J. 2013;449(2):437–48. https://doi.org/10.1042/bj20120343.CrossRefPubMed

65.

Li JH, Huang W, Lin P, Wu B, Fu ZG, Shen HM, et al. N-linked glycosylation at Asn152 on CD147 affects protein folding and stability: promoting tumour metastasis in hepatocellular carcinoma. Sci Rep. 2016;6:35210. https://doi.org/10.1038/srep35210.CrossRefPubMedPubMedCentral

66.

Liu S, Li S, Zhang Y, Wang Y, Zhu Y, Wang B, et al. Purification of a polyclonal antibody against CD147 for ELISA using antigenimmunoaffinity chromatography. Mol Med Rep. 2017;15(6):4035–40. https://doi.org/10.3892/mmr.2017.6523.CrossRefPubMedPubMedCentral

67.

Cui J, Huang W, Wu B, Jin J, Jing L, Shi WP, et al. N-glycosylation by N-acetylglucosaminyltransferase V enhances the interaction of CD147/basigin with integrin beta1 and promotes HCC metastasis. J Pathol. 2018;245(1):41–52. https://doi.org/10.1002/path.5054.CrossRefPubMedPubMedCentral

68.

Ru NY, Cui LB, Jiao B, Zhang L, Jiang S, Yu ZB. Glycosylated CD147 reduces myocardial collagen cross-linking in cardiac hypertrophy. J Cell Biochem. 2018;56:7. https://doi.org/10.1002/jcb.26713.CrossRef

69.

Liu C, Qiu H, Lin D, Wang Z, Shi N, Tan Z, et al. c-Jun-dependent beta3GnT8 promotes tumorigenesis and metastasis of hepatocellular carcinoma by inducing CD147 glycosylation and altering N-glycan patterns. Oncotarget. 2018;9(26):18327–40. https://doi.org/10.18632/oncotarget.24192.CrossRefPubMedPubMedCentral

70.

Herraiz C, Garcia-Borron JC, Jimenez-Cervantes C, Olivares C. MC1R signaling. Intracellular partners and pathophysiological implications. Biochimica Biophys Acta Mol Basis Dis. 2017;1863(10 Pt A):2448–61. https://doi.org/10.1016/j.bbadis.2017.02.027.CrossRef

71.

Rodriguez CI, Setaluri V. Cyclic AMP (cAMP) signaling in melanocytes and melanoma. Arch Biochem Biophys. 2014;563:22–7. https://doi.org/10.1016/j.abb.2014.07.003.CrossRefPubMed

72.

Pasquali E, Garcia-Borron JC, Fargnoli MC, Gandini S, Maisonneuve P, Bagnardi V, et al. MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project. Int J Cancer. 2015;136(3):618–31. https://doi.org/10.1002/ijc.29018.CrossRefPubMed

73.

Salazar-Onfray F, Lopez M, Lundqvist A, Aguirre A, Escobar A, Serrano A, et al. Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker. Br J Cancer. 2002;87(4):414–22. https://doi.org/10.1038/sj.bjc.6600441.CrossRefPubMedPubMedCentral

74.

Herraiz C, Sanchez-Laorden BL, Jimenez-Cervantes C, Garcia-Borron JC. N-glycosylation of the human melanocortin 1 receptor: occupancy of glycosylation sequons and functional role. Pigment Cell Melanoma Res. 2011;24(3):479–89. https://doi.org/10.1111/j.1755-148X.2011.00848.x.CrossRefPubMed

75.

Qu QX, Xie F, Huang Q, Zhang XG. Membranous and cytoplasmic expression of PD-L1 in ovarian cancer cells. Cell Physiol Biochem. 2017;43(5):1893–906. https://doi.org/10.1159/000484109.CrossRefPubMed

76.

Kondo K, Shaim H, Thompson PA, Burger JA, Keating M, Estrov Z, et al. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia. 2017. https://doi.org/10.1038/leu.2017.304.CrossRefPubMedPubMedCentral

77.

Geng Q, Jiao P, Jin P, Su G, Dong J, Yan B. PD-1/PD-L1 inhibitors for immuno-oncology: from antibodies to small molecules. Curr Pharm Des. 2017;56:67. https://doi.org/10.2174/1381612823666171004120152.CrossRef

78.

Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, et al. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Can Res. 2016;76(23):6964–74. https://doi.org/10.1158/0008-5472.can-16-0258.CrossRef

79.

Fessas P, Lee H, Ikemizu S, Janowitz T. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol. 2017;44(2):136–40. https://doi.org/10.1053/j.seminoncol.2017.06.002.CrossRefPubMedPubMedCentral

80.

Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2017. https://doi.org/10.1093/annonc/mdx642.CrossRefPubMedCentral

81.

Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632. https://doi.org/10.1038/ncomms12632.CrossRefPubMedPubMedCentral

82.

Tan S, Zhang H, Chai Y, Song H, Tong Z, Wang Q, et al. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nat Commun. 2017;8:14369. https://doi.org/10.1038/ncomms14369.CrossRefPubMedPubMedCentral

83.

Kyriakopoulou K, Kefali E, Piperigkou Z, Bassiony H, Karamanos NK. Advances in targeting epidermal growth factor receptor signaling pathway in mammary cancer. Cell Signal. 2018;51:99–109. https://doi.org/10.1016/j.cellsig.2018.07.010.CrossRefPubMed

84.

Kanemura H, Fukushima S, Yamashita J, Jinnin M, Sakai K, Masuguchi S, et al. Serum epidermal growth factor receptor levels in patients with malignant melanoma. Clin Exp Dermatol. 2013;38(2):172–7. https://doi.org/10.1111/ced.12022.CrossRefPubMed

85.

Kenessey I, Kramer Z, Istvan L, Cserepes MT, Garay T, Hegedus B, et al. Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model. Melanoma Res. 2018. https://doi.org/10.1097/cmr.0000000000000488.CrossRefPubMed

86.

Takahashi M, Hasegawa Y, Gao C, Kuroki Y, Taniguchi N. N-glycans of growth factor receptors: their role in receptor function and disease implications. Clin Sci. 2016;130(20):1781–92. https://doi.org/10.1042/cs20160273.CrossRef

87.

Kaszuba K, Grzybek M, Orlowski A, Danne R, Rog T, Simons K, et al. N-Glycosylation as determinant of epidermal growth factor receptor conformation in membranes. Proc Natl Acad Sci USA. 2015;112(14):4334–9. https://doi.org/10.1073/pnas.1503262112.CrossRefPubMedPubMedCentral

88.

Azimzadeh Irani M, Kannan S, Verma C. Role of N-glycosylation in EGFR ectodomain ligand binding. Proteins. 2017;85(8):1529–49. https://doi.org/10.1002/prot.25314.CrossRefPubMed

89.

Yokoe S, Takahashi M, Asahi M, Lee SH, Li W, Osumi D, et al. The Asn418-linked N-glycan of ErbB3 plays a crucial role in preventing spontaneous heterodimerization and tumor promotion. Can Res. 2007;67(5):1935–42. https://doi.org/10.1158/0008-5472.can-06-3023.CrossRef

90.

Whitson KB, Whitson SR, Red-Brewer ML, McCoy AJ, Vitali AA, Walker F, et al. Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor. Biochemistry. 2005;44(45):14920–31. https://doi.org/10.1021/bi050751j.CrossRefPubMed

91.

Liu YC, Yen HY, Chen CY, Chen CH, Cheng PF, Juan YH, et al. Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proc Natl Acad Sci USA. 2011;108(28):11332–7. https://doi.org/10.1073/pnas.1107385108.CrossRefPubMedPubMedCentral

92.

Yen HY, Liu YC, Chen NY, Tsai CF, Wang YT, Chen YJ, et al. Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition. Proc Natl Acad Sci USA. 2015;112(22):6955–60. https://doi.org/10.1073/pnas.1507329112.CrossRefPubMedPubMedCentral

93.

Britain CM, Holdbrooks AT, Anderson JC, Willey CD, Bellis SL. Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death. J Ovarian Res. 2018;11(1):12. https://doi.org/10.1186/s13048-018-0385-0.CrossRefPubMedPubMedCentral

94.

Singh M, Jadhav HR. Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors. Drug Discov Today. 2017. https://doi.org/10.1016/j.drudis.2017.10.004.CrossRefPubMed

95.

Udupa KS, Rajendranath R, Sagar T, Thomas J. Differential toxicities of tyrosine kinase inhibitors in the management of metastatic lung cancer. Indian J Med Paediatr Oncol. 2017;38(1):15–7. https://doi.org/10.4103/0971-5851.203502.CrossRefPubMedPubMedCentral

Title: N-Glycosylation in progression of skin cancer
Authors: Ling Tang
Xiaoping Chen
Xu Zhang
Yeye Guo
Juan Su
Jianglin Zhang
Cong Peng
Xiang Chen
Publication date: 01-06-2019
Publisher: Springer US
Keywords: Melanoma
Melanoma
Skin Cancer
Published in: Medical Oncology / Issue 6/2019
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-019-1270-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2019

Correction to: Expression of Concern: Knockdown of eIF3d inhibits cell proliferation through G2/M phase arrest in non-small cell lung cancer

Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)

Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer

Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL)

Identification of candidate diagnostic and prognostic biomarkers for human prostate cancer: RPL22L1 and RPS21

Timing of treatment in small-cell lung cancer

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage